Search the Newsreel

Greenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027

Greenwich LifeSciences has extended the lock-up period for shares held by its directors, officers, and pre-IPO investors until January 31, 2027. This decision, announced by the Board of Directors, signifies confidence in the company's long-term strategy and ongoing Phase III clinical trial for GLSI-100, …

Greenwich LifeSciences Directors, Officers Face 100% Lock-Up to 2027

Greenwich LifeSciences (GLSI) announced an extension of the lock-up period for shares held by its directors, officers, and pre-IPO investors until January 31, 2027. This move, which restricts stock sales unless modified by the Board, is accompanied by positive clinical trial updates for their …

Greenwich LifeSciences (GLSI) Expected to Post Earnings on Thursday

Greenwich LifeSciences (GLSI) is projected to announce its Q2 2026 earnings before market open on Thursday, August 13th, with analysts anticipating a loss of $0.33 per share. The company's stock currently trades at $14.39, significantly below its 52-week high, and has a market capitalization …

What’s Driving GLSI Stock Today?

Greenwich LifeSciences (GLSI) stock rose over 7% after providing an update on its delayed Form 10-K filing, easing Nasdaq listing concerns. The delay was attributed to accounting adjustments related to stronger-than-expected patient enrollment in its Phase III breast cancer trial. With the filing nearing …

Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock

Greenwich LifeSciences CEO Snehal Patel recently purchased 2,200 shares of company stock for a total of $29,555. These transactions occurred on July 28 and July 29, 2026, at prices between $13.10 and $13.59 per share. The insider buying comes as the stock has declined …

Understanding the Setup: (GLSI) and Scalable Risk

This article provides an AI-generated analysis of Greenwich Lifesciences Inc. (GLSI), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes the importance …

Form 4 Greenwich Lifesciences Inc For: 30 July By Investing.com

This article from Investing.com is a brief report on a Form 4 filing for Greenwich Lifesciences Inc. dated July 30. It provides the stock symbol GLSI and notes a -3.71% change. The content primarily consists of the title and symbol, suggesting it's an automated …

GLSI|Greenwich Lifesciences Inc|Price:12.720|Chg%:-0.730

This article provides a comprehensive financial overview of Greenwich Lifesciences Inc. (GLSI), including its stock performance, market capitalization, and detailed financial statements. It highlights key financial indicators like EPS, Revenue, and Net Profit across various quarters, along with a summary of its balance sheet …

Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Greenwich Lifesciences Inc (GLSI), rating its overall financial score at 6.92 out of 385 in its industry. While its financial status is robust, the company's operating efficiency is low, and key financial data for several categories …

Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares

Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys

Greenwich LifeSciences (NASDAQ: GLSI) CEO and CFO, Snehal Patel, recently purchased 3,600 shares of common stock in open-market transactions. These purchases occurred on July 23 and July 24, 2026, at prices of $13.14 and $12.88 per share respectively, increasing his direct holdings to over …

Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for Greenwich Lifesciences Inc (GLSI). It states that no dividend data is available, as a total of $0.00 has been distributed in dividends over the past five years. The page also displays current stock prices and …

Greenwich Lifesciences Inc (GLSI) Institutional Confidence

This article analyzes the institutional confidence score for Greenwich Lifesciences Inc (GLSI), noting its current score of 3.00, ranking 192 out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 19.42% quarter-over-quarter, reaching 11.38%. It also details …

Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History

This article provides detailed financial information on Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company focused on cancer immunotherapies. It covers the company's stock performance, key financial metrics, news, analyst ratings, and a company overview highlighting its lead product candidate GP2 for breast cancer. …

Greenwich LifeSciences Gets UK Clearance to Expand Breast Cancer Trial

Greenwich LifeSciences has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to expand its Phase III clinical trial for GP2 into the United Kingdom. This expansion will allow more breast cancer patients to participate in the trial, which focuses on …

UK approval could add 5-10 sites to Greenwich LifeSciences trial

Greenwich LifeSciences (NASDAQ: GLSI) announced UK regulatory approval to expand its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences. This approval will allow the company to add 5-10 UK sites to the existing 170-180 sites in the US and …

Greenwich LifeSciences gains UK approval for breast cancer trial By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) has received UK regulatory approval to expand its Phase III clinical trial FLAMINGO-01 into the United Kingdom, adding 5-10 UK sites. The trial evaluates GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences, and is being conducted in collaboration with The …

Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial

Greenwich LifeSciences has received UK regulatory approval to expand its Phase III FLAMINGO-01 breast cancer trial into the United Kingdom, allowing for the addition of 5-10 new clinical sites. This expansion builds on existing sites in the US and Europe and is a collaborative …

Brokers Set Expectations for GLSI Q1 Earnings

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

Greenwich LifeSciences, Inc. announced regulatory approval to expand its Phase III clinical trial, FLAMINGO-01, into the United Kingdom. This expansion will add 5-10 UK sites in collaboration with The Royal Marsden, aiming to offer participation to the UK's large population. The trial evaluates GLSI-100, …

Greenwich trial opens enrollment to patients representing about 55% of population

Greenwich LifeSciences (GLSI) provided clinical updates for its Phase III FLAMINGO-01 breast cancer trial, which evaluates GLSI-100. The trial design has been expanded to include non-HLA-A*02 patients, representing about 55% of the population, which is expected to increase enrollment by 122% and accelerate the …

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences (GLSI) provided clinical updates for its Phase III FLAMINGO-01 trial, reporting that its Data Safety Monitoring Board recommended continuing the study without modification. The company announced regulatory approval from the FDA and EMA for previously planned modifications to increase study size, enrollment …

The Technical Signals Behind (GLSI) That Institutions Follow

This article analyzes the technical signals for Greenwich Lifesciences Inc. (GLSI) that institutions monitor. It highlights divergent sentiment, indicating choppy conditions and an ongoing breakdown with elevated downside risk. The report provides AI-generated trading strategies (position, momentum, and risk hedging) and a multi-timeframe signal …

Greenwich LifeSciences Becomes Oversold (GLSI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength …

Greenwich unifies 180-site FLAMINGO-01 trial protocol

Greenwich LifeSciences (NASDAQ:GLSI) announced that European regulators approved combining HLA-A 02 and non-HLA-A 02 patients in the randomized arms of its FLAMINGO-01 trial. This unification, already adopted by U.S. sites, is expected to accelerate enrollment and supports a potential approval pathway for both HLA …

Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01

Greenwich LifeSciences has received European Medicines Agency (EMA) approval to combine both HLA-A*02 and non-HLA-A*02 patient populations in its FLAMINGO-01 clinical trial, mirroring a prior FDA approval. This change standardizes the protocol across US and European sites, potentially doubling the market for GP2 and …

Greenwich LifeSciences expands trial enrollment in Europe By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) has announced that the European Medicines Agency approved the inclusion of both HLA-A02 and non-HLA-A02 patients in its FLAMINGO-01 Phase III clinical trial, aligning European and U.S. protocols. The company, which is evaluating GLSI-100 to prevent breast cancer recurrences, reported a …

A breast cancer trial can now enroll patients who waited up to a year

Greenwich LifeSciences (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has approved combining both HLA-A*02 and non-HLA-A*02 patients in the randomized arms of its Phase III FLAMINGO-01 trial for GLSI-100, which aims to prevent breast cancer recurrences. This decision unifies the protocol across …